This is a working overview of Hepatocyte growth factor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
==== MeSH E05.318.760 – epidemiologic study characteristics ==== MeSH E05.318.760.500 – epidemiologic studies MeSH E05.318.760.500.500 – case-control studies MeSH E05.318.760.500.500.500 – retrospective studies MeSH E05.318.760.500.750 – cohort studies MeSH E05.318.760.500.750.500 – longitudinal studies MeSH E05.318.760.500.750.500.350 – follow-up studies MeSH E05.318.760.500.750.500.650 – prospective studies MeSH E05.318.760.500.875 – cross-sectional studies MeSH E05.318.760.500.950 – seroepidemiologic studies MeSH E05.318.760.500.950.375 – hiv seroprevalence MeSH E05.318.760.535 – clinical trials MeSH E05.318.760.535.200 – clinical trials, phase i MeSH E05.318.760.535.210 – clinical trials, phase ii MeSH E05.318.760.535.220 – clinical trials, phase iii MeSH E05.318.760.535.230 – clinical trials, phase iv MeSH E05.318.760.535.365 – controlled clinical trials MeSH E05.318.760.535.365.500 – randomized controlled trials MeSH E05.318.760.535.500 – multicenter studies MeSH E05.318.760.550 – feasibility studies MeSH E05.318.760.565 – intervention studies MeSH E05.318.760.750 – pilot projects MeSH E05.318.760.875 – sampling studies MeSH E05.318.760.900 – twin studies
== Medical uses == Vancomycin is indicated for the treatment of serious, life-threatening infections by Gram-positive bacteria of both aerobic and anaerobic types that are unresponsive to other antibiotics. The increasing emergence of vancomycin-resistant enterococci (VRE) has resulted in the development of guidelines for use by the Centers for Disease Control Hospital Infection Control Practices Advisory Committee. These guidelines restrict use of vancomycin to these indications:
Mammals serve a major role in science as experimental animals, both in fundamental biological research, such as in genetics, and in the development of new medicines, which must be tested exhaustively to demonstrate their safety. Millions of mammals, especially mice and rats, are used in experiments each year. A knockout mouse is a genetically modified mouse with an inactivated gene, replaced or disrupted with an artificial piece of DNA. They enable the study of sequenced genes whose functions are unknown. A small percentage of the mammals are non-human primates, used in research for their similarity to humans. Despite the benefits domesticated mammals had for human development, humans have an increasingly detrimental effect on wild mammals across the world. It has been estimated that the mass of all wild mammals has declined to only 4% of all mammals, with 96% of mammals being humans and their livestock now (see figure). In fact, terrestrial wild mammals make up only 2% of all mammals.
Sources: en.wikipedia.org
During the War of the Triple Alliance, Peru was a country that protested against the alleged attempts to conquer Paraguay by the member countries of the Triple Alliance (of which Argentina was a part together with Uruguay and Brazil). For the rest of the continent, this war was perceived as an attempt to conquer and divide Paraguay among the allies. The attempt against the independence of one of the countries of the continent was feared as a terrible precedent for potential geopolitical disorders and possible expansionist projects in the governments of the area, Argentina being very frowned upon in the eyes of Peru. The controversial Secret Treaty of the Triple Alliance was seen in Peruvian diplomacy as a violation of Paraguay's sovereignty and integrity as a country. Thus, the perception of that war was understood, in the public eye, as the arrogance of 3 allied countries that wanted to seize Paraguay's territory and even destroy its sovereignty, generating analogies with the Second French intervention in Mexico or the Spanish-South American War, that happened simultaneously during the 1860s, comparing them as a form of imperialism not different from that of the Europeans. Seen in this way, no distinction was made regarding a conquest, especially of a Latin American country, by an American government or a European government, in the eyes of society, both acts were reprehensible.
The HGSA is governed by a council, presided over by the president. The day-to-day strategic decision making is undertaken by an executive of council, consisting of the president, vice-president, treasurer and secretary. The Society employs a chief executive officer to run the administrative functions of the organization. Executive members of HGSA council are elected to their positions by popular vote from the membership. The remainder of the council is representative of the membership. The jurisdictions are represented by the chairpersons of HGSA branches, while the special interest groups are represented by their chairs. Council has the capacity to establish committees to undertake long-term high-level activities of the society. Longstanding committees include the Scientific Programme Committee; Annual Scientific Meeting Local Organising Committee; and the Education, Ethics and Social Issues Committee.
== Temperature regulation == In addition to their role in weight control, dynorphins have been found to regulate body temperature. Opioid peptides were first investigated in hyperthermia, where it was found that μ-opioid receptor (MOR) agonists stimulate this response when injected into the periaqueductal gray (PAG) region of the brain. Xin et al. showed that delivery of dynorphin A1-17 (a KOR agonist) through microdialysis into the PAG region induced hypothermia in rats. The authors found that the severity of hypothermia was proportional to the dose of dynorphin A1-17 administered. Hypothermia could be prevented by administering KOR antagonist nor-BNI to the rat. Xin et al. hypothesized that while MOR agonists mediate hyperthermia, KOR agonists, such as dynorphin, mediate hypothermia. Sharma and Alm found that subjecting rats to heat (38˚C) caused dynorphins to be upregulated in the cerebral cortex, hippocampus, cerebellum, and the brain stem. Further, authors found that administration of nitric oxide synthase (NOS) inhibitors reduced dynorphin A1-17 levels in the brain and attenuated symptoms related to heat stress. Sharma and Alm concluded that hyperthermia increases dynorphin levels, which may cause damage and promote heat stress reaction. They further hypothesized that nitric oxide was part of this mechanism. Ansonoff et al. found that hypothermic effects are mediated through K1 (κ-opioid receptor 1), but not K2.
Sources: en.wikipedia.org
ELGA LabWater is the laboratory water brand name of Veolia Water Solutions & Technologies. ELGA manufactures, supplies and services water purification systems for use in general, R&D, healthcare and clinical laboratories. Its offices and distributors are located in more than 60 countries.
== History == The application of mass spectrometry to study proteins became popularized in the 1980s after the development of MALDI and ESI. These ionization techniques have played a significant role in the characterization of proteins. (MALDI) Matrix-assisted laser desorption ionization was coined in the late 1980s by Franz Hillenkamp and Michael Karas. Hillenkamp, Karas and their fellow researchers were able to ionize the amino acid alanine by mixing it with the amino acid tryptophan and irradiated with a pulse 266 nm laser. Though important, the breakthrough did not come until 1987. In 1987, Koichi Tanaka used the "ultra fine metal plus liquid matrix method" and ionized biomolecules the size of 34,472 Da protein carboxypeptidase-A. In 1968, Malcolm Dole reported the first use of electrospray ionization with mass spectrometry. Around the same time MALDI became popularized, John Bennett Fenn was cited for the development of electrospray ionization. Koichi Tanaka received the 2002 Nobel Prize in Chemistry alongside John Fenn, and Kurt Wüthrich "for the development of methods for identification and structure analyses of biological macromolecules." These ionization methods have greatly facilitated the study of proteins by mass spectrometry. Consequently, protein mass spectrometry now plays a leading role in protein characterization.
=== Thermoelectric refrigeration === Thermoelectric cooling uses the Peltier effect to transfer heat when an electric current passes through junctions of dissimilar thermoelectric materials. Thermoelectric cooling is used in applications including electronic thermal management and scientific instrumentation. Thermoelectric coolers have no mechanical moving parts and can be compact and lightweight, making them useful where the size, mass or mechanical complexity of conventional refrigeration is undesirable. For larger temperature differences, thermoelectric modules can be arranged in multiple stages, with successive stages removing both the heat transferred from the cooled region and heat generated by preceding stages. The performance of a thermoelectric cooler depends on factors including thermoelectric material properties, operating temperatures, electrical current and thermal resistances. For conventional space-cooling and food-refrigeration applications, thermoelectric systems generally have a lower coefficient of performance than vapor-compression systems and therefore require more electrical input for the same cooling load.
== Career == King joined Massachusetts Institute of Technology in 1959 as an assistant professor of chemical engineering to become director of the School of Chemical Engineering Practice station at the Exxon (then Esso) Bayway refinery in New Jersey. In 1963, King joined University of California, Berkeley as assistant professor of chemical engineering, becoming associate professor in 1966 and full professor in 1969. From 1967 to 1972, he served as the vice chairman of Department of Chemical Engineering. He then served as the chairman of the department from 1972 to 1981. In 1981, King was appointed as the dean of College of Chemistry and later in 1987 as the provost of the Professional Schools and Colleges, a position in which he served until 1994. At the time of his appointment, King was the first chemical engineer to become dean of the College of Chemistry at Berkeley. King was appointed the vice provost for research for the entire nine-campus University of California in 1994. In 1995 he became provost and senior vice president for academic affairs, again university-wide. During his time as UC provost, King helped launch the new, tenth UC campus at Merced, the California Digital Library, and eScholarship, the University of California's open access, electronic repository for publications by UC authors. He returned to UC Berkeley in 2004 as the director of Center for Studies in Higher Education, serving in this position for a full decade until 2014.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.